Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2

Environmental Toxicology and Pharmacology

Volumn 26, Issue 1, 2008, Pages 102-108

  Wortelboer, Heleen M ^a   Balvers, Michiel G J ^a   Usta, Mustafa ^a   van Bladeren, Peter J ^b,c   Cnubben, Nicole H P ^a  

^a TNO   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Arsenic trioxide; Cisplatin; Glutathione; Mercury chloride; MRP1; MRP2

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ARSENIC TRIOXIDE; CALCEIN; CISPLATIN; GLUTATHIONE; MERCURIC CHLORIDE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2;

ANIMAL CELL; ARTICLE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; KIDNEY CELL; MEMBRANE VESICLE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPORT KINETICS;

EID: 42149139427     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2008.02.006     Document Type: Article

References (51)

1. 2-treated tubular MDCK cells. Toxicology 206 (2005) 137
2. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113 (1985) 548
3. Ballatori N. Transport of toxic metals by molecular mimicry. Environ. Health Perspect. 110 (2002) 689
4. Ballatori N., and Clarkson T.W. Biliary secretion of glutathione and of glutathione-metal complexes. Fundam. Appl. Toxicol. 5 (1985) 816
5. Ballatori N., Hammond C.L., Cunningham J.B., Krance S.M., and Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 204 (2005) 238
6. Bernareggi A., Torti L., Facino R.M., Carini M., Depta G., Casetta B., et al. Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry. Evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats and cancer patients. J. Chromatogr. Biomed. Appl. 669 (1995) 247
7. Borenfreund E., and Peurner J.A. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett. 24 (1985) 119
8. Borst P., Evers R., Kool M., and Wijnholds J.J. A family of drug transporters: the multidrug resistance-associated proteins. Natl. Cancer Inst. 92 (2000) 1295
9. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002) 537
10. Borst P., Zelcer N., van de Wetering K., and Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett. 580 (2006) 1085
11. Chang X.B., Hou Y.X., and Riordan J.R. ATPase activity of purified multidrug resistance-associated protein. J. Biol. Chem. 272 (1997) 30962
12. Ciarimboli G., Ludwig T., Lang D., Pavenstadt H., Koepsell H., Piechota H.J., et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167 (2005) 1477
13. Cnubben N.H.P., Wortelboer H.M., Van Zanden J.J., Rietjens J.M.C.M., and Van Bladeren P.J. Metabolism of ABC drug transporter inhibitors; complicating factor for multidrug resistance. Expert Opin. Drug Metab. Toxicol. 1 (2005) 219
14. Csanaky I., and Gregus Z. Role of glutathione in reduction of arsenate and of gamma-glutamyltranspeptidase in disposition of arsenite in rats. Toxicology 207 (2005) 91
15. Cui Y., König J., Buchholz J.K., Spring H., Leier I., and Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55 (1999) 929
16. Dabrowiak J.C., Goodisman J., and Souid A.-K. Kinetic study of the reaction of cisplatin with thiols. Drug Metab. Dispos. 30 (2002) 1378
17. Deeley R.G., and Cole S.P. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580 (2006) 1103
18. Delnomdedieu M., Basti M.M., Otvos J.D., and Thomas D.J. Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study. Chem. Biol. Interact. 90 (1994) 139
19. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L.C.J.M., et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101 (1998) 1310
20. Evers R., Kool M., Smith A.J., van Deemter L., de Haas M., and Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2 mediated transport. Br. J. Cancer 83 (2000) 366
21. Gailer J., and Lindner W. On-column formation of arsenic-glutathione species detected by size-exclusion chromatography in conjunction with arsenic-specific detectors. J. Chromatogr. Biomed. Sci. Appl. 716 (1998) 83
22. Guminski A.D., Balleine R.L., Chiew Y., Webster L.R., Tapner M., Farrell G.C., Harnett P.R., and Fazio A. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol. Oncol. 100 (2006) 239
23. Giaccone G. Clinical perspectives on platinum resistance. Drugs 59 (2000) 9
24. Goto S., Iida T., Cho S., Oka M., Kohno S., and Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic. Res. 31 (1999) 549
25. Hagrman D., Goodisman J., and Souid A.S.-K. Kinetic study on the reactions of platinum drugs with glutathione. J. Pharmacol. Exp. Ther. 308 (2004) 658
26. Haimeur A., Conseil G., Deeley R.G., and Cole S.P.C. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate and regulation. Curr. Drug Metab. 5 (2004) 21
27. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59 (1999) 2532
28. Ishikawa T., Bao J.J., Yamane Y., Akimaru K., Frindrich K., Wright C.D., et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem. 271 (1996) 14981
29. Itoh Y., Tamai M., Yokogawa K., Nomura M., Moritani S., Suzuki H., et al. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res. 22 (2002) 1649
30. Kala S.V., Neely M.W., Kala G., Prater C.I., Atwood D.W., Rice J.S., et al. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 275 (2000) 33404
31. Kauffmann H.M., Pfannschmidt S., Zoller H., Benz A., Vorderstemann B., Webster J.I., et al. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 171 (2002) 137
32. Leslie E.M., Deeley R.G., and Cole S.P. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos. 31 (2003) 11
33. Leslie E.M., Haimeur A., and Waalkes M.P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1): evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279 (2004) 32700
34. Leslie E.M., Ito K., Upaddhaya P., Hecht S.S., Deeley R.G., and Cole S.P. Transport of the beta-O-Glucuronide conjugate of the tobacco-specific carcinogen 4-methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). requirement for glutathione or a non-sulfur containing analog. J. Biol. Chem. 276 (2001) 27846
35. Loe D.W., Almquist K.C., Deeley R.G., and Cole S.P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 271 (1996) 9675
36. Loe D.W., Deeley R.G., and Cole S.P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58 (1998) 5130
37. Loe D.W., Deeley R.G., and Cole S.P. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J. Pharmacol. Exp. Ther. 293 (2000) 530
38. Loe D.W., Oleschukm C.J., Deeley R.G., and Cole S.P. Structure-activity studies of verapamil analogs that modulate transport of leukotriene C4 and reduced glutathione by multidrug resistance protein MRP1. Biochem. Biophys. Res. Commun. 275 (2000) 795
39. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., and Serabjit Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmcol. Exp. Ther. 299 (2001) 620
40. Qian Y.M., Song W.C., Cui H., Cole S.P., and Deeley R.G. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J. Biol. Chem. 276 (2001) 6404
41. Pendyala L., Creaven P.J., Perez R., and Zdanowicz J.R. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol. 36 (1995) 271
42. Rappa G., Lorico A., Flavelli R.A., and Sratorelli A.C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 57 (1997) 5232
43. Salerno M., Petroutsa M., and Garnier-Suillerot A. The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation. J. Bioenerg. Biomembr. 34 (2002) 135
44. Sarkadi B., Price E.M., Boucher R.C., Germann U.A., and Scarborough G.A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267 (1992) 4854
45. Sharp S.Y., Smith V., Hobbs S., and Kelland L.R. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br. J. Cancer 78 (1998) 175
46. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 9 (1997) 3354
47. Vernhet L., Allain N., Bardiau C., Anger J.P., and Fardel O. Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. Toxicology 142 (2000) 127
48. Watabe M., Kobayashi T., Kawahashi T., Hino A., Watanabe T., Mikami T., et al. Preparation, 195Pt NMR spectra and biological activity of platinum (IV) complexes with dipeptides. J. Inorg. Biochem. 73 (1999) 1
49. Wortelboer H.M., Usta M., van der Velde A.E., Boersma M.G., Spenkelink B., van Zanden J.J., et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem. Res. Toxicol. 16 (2003) 1642
50. Wortelboer H.M., Usta M., van Zanden J.J., van Bladeren P.J., Rietjens I.M., and Cnubben N.H. Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha, beta-unsaturated carbonyl compounds. Biochem. Pharmacol. 69 (2005) 1879
51. Zalups R.K. Molecular interactions with mercury in the kidney. Pharmacol. Rev. 52 (2000) 113